Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms.
It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
| Country | United States |
| Founded | 1965 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Michael Breen |
Contact Details
Address: 315 Montgomery Street, 10th Floor San Francisco, California 94104 United States | |
| Phone | 415 919 4040 |
| Website | gtbiopharma.com |
Stock Details
| Ticker Symbol | GTBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109657 |
| CUSIP Number | 36254L209 |
| ISIN Number | US36254L3087 |
| Employer ID | 94-1620407 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Martin Breen L.L.B. | Chief Executive Officer and Executive Chairman |
| Alan Louis Urban CPA | Chief Financial Officer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 424B3 | Prospectus |
| Jul 2, 2025 | EFFECT | Notice of Effectiveness |
| Jun 27, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 11, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 2, 2025 | SCHEDULE 13G/A | Filing |